嵌合抗原受体 T 细胞 (CAR-T) 在血液恶性肿瘤中显示出显着的疗效，但在实体瘤中的反应有限。在实体瘤中，CAR-T细胞疗法尤其在脑肿瘤中得到探索。 CAR-T细胞在各种类型的脑肿瘤中表现出有限的临床疗效，这是由于多种因素阻碍了其活性，包括肿瘤抗原异质性、CAR-T细胞接触脑肿瘤细胞的机会有限、CAR-T细胞运输有限以及体内持久性和高度免疫抑制肿瘤微环境的存在。尽管有这些考虑，最近的一些研究表明，GD2-CAR-T 细胞对弥漫性中线胶质瘤和神经母细胞瘤以及 CARv3-TEAM-E 细胞在胶质母细胞瘤中具有良好的抗肿瘤活性。然而，需要采取策略来提高 CAR-T 细胞在脑肿瘤中的疗效，包括具有多种抗原靶向的先进 CAR-T 细胞设计和联合疗法。

Chimeric antigen receptor T cells (CAR-Ts) have shown a remarkable efficacy in hematological malignancies but limited responses in solid tumors. Among solid tumors, CAR-T cell therapy has been particularly explored in brain tumors. CAR-T cells have shown a limited clinical efficacy in various types of brain tumors due to several factors that have hampered their activity, including tumor antigen heterogeneity, the limited access of CAR-T cells to brain tumor cells, limited CAR-T cell trafficking and in vivo persistence and the presence of a highly immunosuppressive tumor microenvironment. Despite these considerations, some recent studies have shown promising antitumor activity of GD2-CAR-T cells on diffuse midline gliomas and neuroblastomas and of CARv3-TEAM-E cells in glioblastomas. However, strategies are required to improve the effect of CAR-T cells in brain tumors, including advanced CAR-T cell design with multiple antigenic targeting and incorporation of combination therapies.